Mechanisms of α-Synuclein Induced Synaptopathy in Parkinson's Disease

被引:234
|
作者
Bridi, Jessika C. [1 ]
Hirth, Frank [1 ]
机构
[1] Kings Coll London, Dept Basic & Clin Neurosci, Maurice Wohl Clin Neurosci Inst, Inst Psychiat Psychol & Neurosci, London, England
来源
FRONTIERS IN NEUROSCIENCE | 2018年 / 12卷
基金
英国生物技术与生命科学研究理事会; 英国医学研究理事会;
关键词
Parkinson's disease; synapse; SNARE complex; active zone; dopamine; alpha-synuclein; synaptopathy; neurodegeneration; LEWY BODY DEMENTIA; TYROSINE-HYDROXYLASE PHOSPHORYLATION; VESICULAR MONOAMINE TRANSPORTER-2; PRESYNAPTIC ACTIVE ZONE; SYNAPTIC VESICLE CYCLE; NEURODEGENERATIVE DISEASES; DOPAMINE TRANSPORTER; NEUROTRANSMITTER RELEASE; CELL-DEATH; MITOCHONDRIAL DYSFUNCTION;
D O I
10.3389/fnins.2018.00080
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Parkinson's disease (PD) is characterized by intracellular inclusions of aggregated and misfolded alpha-Synuclein (alpha-Syn), and the loss of dopaminergic (DA) neurons in the brain. The resulting motor abnormalities mark the progression of PD, while non-motor symptoms can already be identified during early, prodromal stages of disease. Recent studies provide evidence that during this early prodromal phase, synaptic and axonal abnormalities occur before the degenerative loss of neuronal cell bodies. These early phenotypes can be attributed to synaptic accumulation of toxic alpha-Syn. Under physiological conditions, alpha-Syn functions in its native conformation as a soluble monomer. However, PD patient brains are characterized by intracellular inclusions of insoluble fibrils. Yet, oligomers and protofibrils of alpha-Syn have been identified to be the most toxic species, with their accumulation at presynaptic terminals affecting several steps of neurotransmitter release. First, high levels of alpha-Syn alter the size of synaptic vesicle pools and impair their trafficking. Second, alpha-Syn overexpression can either misregulate or redistribute proteins of the presynaptic SNARE complex. This leads to deficient tethering, docking, priming and fusion of synaptic vesicles at the active zone (AZ). Third, alpha-Syn inclusions are found within the presynaptic AZ. accompanied by a decrease in AZ protein levels. Furthermore, alpha-Syn overexpression reduces the endocytic retrieval of synaptic vesicle membranes during vesicle recycling. These presynaptic alterations mediated by accumulation of alpha-Syn, together impair neurotransmitter exocytosis and neuronal communication. Although alpha-Syn is expressed throughout the brain and enriched at presynaptic terminals, DA neurons are the most vulnerable in PD, likely because alpha-Syn directly regulates dopamine levels. Indeed, evidence suggests that alpha-Syn is a negative modulator of dopamine by inhibiting enzymes responsible for its synthesis. In addition, alpha-Syn is able to interact with and reduce the activity of VMAT2 and DAT. The resulting dysregulation of dopamine levels directly contributes to the formation of toxic alpha-Syn oligomers. Together these data suggest a vicious cycle of accumulating alpha-Syn and deregulated dopamine that triggers synaptic dysfunction and impaired neuronal communication, ultimately causing synaptopathy and progressive neurodegeneration in Parkinson's disease.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] Immunological features of α-synuclein in Parkinson's disease
    Roodveldt, Cintia
    Christodoulou, John
    Dobson, Christopher M.
    [J]. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2008, 12 (5B) : 1820 - 1829
  • [42] Environmental toxins and α-synuclein in Parkinson’s disease
    Yanying Liu
    Hui Yang
    [J]. Molecular Neurobiology, 2005, 31 : 273 - 282
  • [43] Alpha-synuclein and Parkinson's disease
    Golbe, LI
    [J]. MOVEMENT DISORDERS, 1999, 14 (01) : 6 - 9
  • [44] Expression of α-synuclein mRNA in Parkinson's disease
    Papapetropoulos, Spiridon
    Shehadeh, Lina
    Shehadeh, Lina
    [J]. MOVEMENT DISORDERS, 2007, 22 (07) : 1057 - 1059
  • [45] Biomarkers and the Role of α-Synuclein in Parkinson's Disease
    Du, Tingting
    Wang, Le
    Liu, Weijin
    Zhu, Guanyu
    Chen, Yingchuan
    Zhang, Jianguo
    [J]. FRONTIERS IN AGING NEUROSCIENCE, 2021, 13
  • [46] Topography of α-synuclein pathology in Parkinson's disease
    Kalaitzakis, M. E.
    Graeber, M. B.
    Gentleman, S. M.
    Pearce, R. K. B.
    [J]. MOVEMENT DISORDERS, 2007, 22 : S7 - S7
  • [47] Parkinson's disease biomarkers based on α-synuclein
    Fayyad, Muneera
    Salim, Safa
    Majbour, Nour
    Erskine, Daniel
    Stoops, Erik
    Mollenhauer, Brit
    El-Agnaf, Omar M. A.
    [J]. JOURNAL OF NEUROCHEMISTRY, 2019, 150 (05) : 626 - 636
  • [48] Aggregation of α-synuclein in the pathogenesis of Parkinson's disease
    Iwatsubo, T
    [J]. JOURNAL OF NEUROLOGY, 2003, 250 (Suppl 3) : 11 - 14
  • [49] α-Synuclein and Mitochondrial Dysfunction in Parkinson's Disease
    Mullin, Stephen
    Schapira, Anthony
    [J]. MOLECULAR NEUROBIOLOGY, 2013, 47 (02) : 587 - 597
  • [50] Role of Apolipoproteins and α-Synuclein in Parkinson’s Disease
    Fatemeh Nouri Emamzadeh
    [J]. Journal of Molecular Neuroscience, 2017, 62 : 344 - 355